Korro Bio (NASDAQ:KRRO) aims to "discover, develop and commercialize a new class of RNA therapies informed by human genetics ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

The first two and some forms of obesity are associated with single-point mutations. Some other companies using ADAR enzymes ...

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...

Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...

Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 ...

Vertex may have pivoted away from the space, but candidates in development by Arrowhead/Takeda, Wave, Korro and others could ...

“Our primary focus is the development of 100 per cent compostable, bio-derived packaging for use as sprays, films, bottles, caps and wrappers, which are engineered to fully break down in compost, land ...

BENGALURU, MUMBAI: The highly anticipated biography of Ratan Tata, which hit bookstores on Friday, less than three weeks after his death, was reportedly published without the late industrialist ...